title: Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer.
abstract: OBJECTIVE
  ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor in the prostate. The purpose of this study was to investigate the expression of EAF2 protein in human prostate cancer specimens along with BPH specimens as a control, and to evaluate potential association of EAF2 expression with clinical characteristics and overall survival of the prostate cancer patients.
  
  
  METHODS
  The expression of EAF2 was evaluated in 44 prostate cancer and 23 BPH tissue specimens using immunohistochemistry. The relationships of EAF2 expression with clinical characteristics and overall survival rates were analyzed by Chi-square test and Kaplan-Meier method.
  
  
  RESULTS
  The immunostaining intensity of EAF2 in BPH specimens was significantly higher than that in prostate cancer (p < 0.05). EAF2 expression decreased significantly in high-grade and advanced-stage human prostate tumors and inversely correlated with PSA level, Gleason scores, bone metastasis and tumor stage. Importantly, loss of EAF2 expression was associated with a significant decrease in patient survival.
  
  
  CONCLUSIONS
  Expression of EAF2 is decreased in prostate carcinogenesis, and EAF2 loss is associated with high-risk patients and poor survival.
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China.
authors.forename: Yachen
authors.initials: Y
authors.lastname: Zang
authors.affiliation: Department of Pathology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China.
authors.forename: Dongrong
authors.initials: D
authors.lastname: Yang
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China.
authors.forename: Boxin
authors.initials: B
authors.lastname: Xue
authors.affiliation: Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Gu
authors.affiliation: Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
authors.forename: Haifeng
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China.
authors.forename: Shaoxiong
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China.
authors.forename: Songlin
authors.initials: S
authors.lastname: Zhou
authors.affiliation: Department of Urology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Ying
authors.affiliation: Department of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.|Department of Molecular Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.|Department of Pathology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China. shanyx1002@yeah.net.
authors.forename: Yuxi
authors.initials: Y
authors.lastname: Shan
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000097:blood / Q000737:chemistry* / Q000473:pathology*; D015996:Survival Rate; D014157:Transcription Factors / Q000032:analysis*
chemical_list: C472771:EAF2 protein, human; D014157:Transcription Factors; D017430:Prostate-Specific Antigen
keywords: ELL-associated factor 2 (EAF2); Overall survival; Prognosis; Prostate cancer